JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arthroplasty, Replacement, Knee
Conditions
Arthroplasty, Replacement, Knee
Trial Timeline
Jun 17, 2019 → Apr 6, 2021
NCT ID
NCT03891524About JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg
JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg is a phase 2 stage product being developed by Bristol Myers Squibb for Arthroplasty, Replacement, Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT03891524. Target conditions include Arthroplasty, Replacement, Knee.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03891524 | Phase 2 | Completed |
Competing Products
9 competing products in Arthroplasty, Replacement, Knee
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DU-176b | Daiichi Sankyo | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503) | Johnson & Johnson | Phase 3 | 77 |
| Zoledronic acid 5mg | Novartis | Approved | 85 |
| Denosumab | Amgen | Phase 2 | 51 |
| Enoxaparin sodium | Sanofi | Phase 3 | 76 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 22 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 49 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |